ArticleCardiology2026
Impact of Inflammatory Disorders on Outcomes in Acute Heart Failure: A Nationwide Analysis.
Article in Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute heart failure (AHF) is characterized by rapid symptom deterioration and high mortality. This study evaluates how eight inflammatory disorders, driven by systemic inflammation, immune dysfunction, and antirheumatic cardiotoxicity, impact in-hospital mortality, complications, and length of stay during AHF admissions.
methodsWe included patients hospitalized with AHF between 2015 and 18 from the National Inpatient Sample (NIS). The population was compared based on inflammatory disease status. The primary endpoint was in-hospital mortality, with additional endpoints: length of stay and in-hospital complications.
resultsA total of 1,042,218 AHF admissions were included in our analysis, of whom 39,485 were diagnosed with CID. Patients with CID were older (72 vs. 71 years, p < 0.001) and more likely to be female (67.8% vs. 47.0%, p < 0.001). In the adjusted multivariable model, CIDs as a whole were not associated with increased in-hospital mortality (OR: 1.05, 95% CI: 0.98-1.12, p = 0.183) or MACE (OR: 1.00, 95% CI: 0.97-1.05, p = 0.765). However, disease-specific analysis revealed that SLE (OR: 1.56, 95% CI: 1.33-1.85, p < 0.001) and SSc (OR: 1.47, 95% CI: 1.14-1.89, p = 0.003) were independently associated with significantly higher mortality. Additionally, MCTD (9.06 days), SSc (6.50 days), and SLE (6.27 days) patients had significantly longer hospitalizations compared to non-CID patients (5.36 days, p < 0.001). Conversely, a significantly lower risk of major bleeding was observed in Ulcerative Colitis (OR: 0.40, 95% CI: 0.24-0.67, p = 0.001), and Sjögren's (OR: 0.43, 95% CI: 0.26-0.72, p = 0.001) cohorts.
conclusionWhile CIDs as a whole were not found to impact acute heart failure mortality, specific systemic autoimmune rheumatic diseases, namely SLE and SSc, carry a significantly higher risk for in-hospital death. The substantially longer lengths of stay observed in SLE, SSc, and MCTD patients likely reflect severe multi-organ vulnerability and higher resource intensity rather than isolated acute cardiovascular events. Furthermore, the observed reduction in major bleeding risk among specific subgroups suggests that CIDs should not be managed as a monolithic group. Clinicians should remain aware of disease-specific risks when managing AHF in patients with systemic autoimmune conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.